HOME >> MEDICINE >> NEWS
Tuberculosis strains stay close to home, say Stanford researchers

STANFORD, Calif. - Taking advantage of the open-air laboratory that is San Francisco, Peter Small, MD, has collected samples of virtually every case of tuberculosis that has occurred in the city for the last 13 years - almost 3,000 total. In this week's advance online edition of The Proceedings of the National Academy of Sciences, the associate professor of infectious diseases and geographic medicine at the Stanford University School of Medicine and his colleagues present a genetic analysis of 100 of these samples. The findings suggest ways the bacteria can escape a host's immune system or develop antibiotic resistance.

The team took its analysis a step further in a second paper, which appears in the same edition of the journal. They found that people from different regions of the world carry different strains of the tuberculosis bacteria, pointing out the importance of sociological interactions in infectious disease transmission. This also raises the possibility that the pathogen evolves within a geographic population group and doesn't spread to other groups.

"It was remarkable how well the genetics mapped to global geography," said Small. "Co-evolution is highly speculative, but it's an intriguing possibility. Most importantly, it's a hypotheses we now have the technology to address."

Tuberculosis causes more adult deaths than any other infectious disease. Worldwide, one person in three is infected, but it remains a problem primarily in the developing world. However, the emergence of tuberculosis strains resistant to multiple drugs in industrialized countries is prompting renewed interest in vaccination.

There has long been anecdotal evidence that tuberculosis bacteria differ throughout the world, said Small, who is currently on leave from Stanford serving as a senior program officer in the Global Health Program of the Bill and Melinda Gates Foundation. Additionally, he said, studies testing tuberculosis vaccines have varied widely
'"/>

Contact: Mitzi Baker
650-725-2106
Stanford University Medical Center
15-Mar-2004


Page: 1 2 3

Related medicine news :

1. Tuberculosis drug combined with virtual reality therapy is effective in treating fear of heights
2. UCSD Medical Center receives NIH contract to set up National Tuberculosis Educational Curriculum
3. Tuberculosis Foundation selects Core Research Scientists
4. New quick test for drug-resistant strains of gonorrhea
5. Nabi StaphVAX elicits antibodies with in vitro activity against antibiotic-resistant Staphylococcus aureus strains
6. War on bacteria could leave drug-resistant strains unchecked
7. New data provide further evidence of effectiveness of targeted delivery of Relenza and efficacy in both A&B strains
8. Indiana University researchers closer to helping hearing-impaired using stem cells
9. Chemicals in tattoo inks need closer scrutiny
10. Researchers close in on breast cancer vaccine
11. Drug companies should disclose adverse events before licensing

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Tuberculosis strains stay close home say Stanford researchers

(Date:4/22/2014)... percent of all lung cancers are small cell ... develop resistance to chemotherapy. However, researchers at Virginia ... insights into the mechanisms leading to this resistance ... Chemotherapies work primarily by mediating B-cell lymphoma 2 ... cell death. Depending on their function, this family ...
(Date:4/22/2014)... 2014Hemoglobin A1c is the standard measurement for assessing glycemic ... of A1c are typically measured every few months in ... model that accurately estimates A1c using self-monitored blood glucose ... Therapeutics ( DTT ), a peer-reviewed journal from ... free on the DTT website at ...
(Date:4/22/2014)... PHILADELPHIA (April 22, 2014) That person we all seem ... take action? Turns out he or she isn,t unable to ... A study of nearly ... about why neurotic people may avoid making decisions and moving ... if action is positive, favorable, good, they just don,t like ...
(Date:4/22/2014)... -- In parallel with modern man ( Homo sapiens ), ... we lived side by side, such as Neanderthals and the ... sapiens survived. What was it in our genetic makeup ... little is known about our unique genetic makeup as distinguished ... fact that we are the only species among them ,to ...
(Date:4/22/2014)... Disease (IBD), a group of chronic inflammatory disorders of ... affects over 1.4 million people in the U.S., and ... there is no cure. , Now, Cincinnati Cancer ... Susan Waltz, PhD, and scientists in her lab have ... genetic study to document the important function for the ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Neurotics don't just avoid action: They dislike it 2Health News:What gave us the advantage over extinct types of humans? 2Health News:Two genes linked to inflammatory bowel disease 2
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: